Financial Snapshot

Revenue
$24.79M
TTM
Gross Margin
52.61%
TTM
Net Earnings
-$84.93M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
288.4%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$69.77M
Q3 2024
Cash
Q3 2024
P/E
-5.770
Nov 29, 2024 EST
Free Cash Flow
-$69.65M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Revenue $27.46M $10.46M $28.65M $13.29M $12.84M $0.00 $0.00 $0.00
YoY Change 162.58% -63.5% 115.61% 3.5%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Revenue $27.46M $10.46M $28.65M $13.29M $12.84M $0.00 $0.00 $0.00
Cost Of Revenue $800.0K $343.0K $2.059M $10.00M $0.00
Gross Profit $26.66M $10.12M $26.59M $2.839M $0.00
Gross Profit Margin 97.09% 96.72% 92.81% 22.11%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Selling, General & Admin $34.31M $15.34M $8.701M $8.340M $10.82M $13.74M $12.77M $15.91M $8.880M $4.530M $1.350M $2.340M
YoY Change 123.69% 76.3% 4.33% -22.92% -21.25% 7.6% -19.74% 79.17% 96.03% 235.56% -42.31%
% of Gross Profit 128.7% 151.66% 32.72% 381.12%
Research & Development $39.81M $19.61M $10.16M $8.843M $19.42M $41.76M $20.59M $20.47M $13.93M $11.92M $3.367M $2.990M
YoY Change 102.95% 93.03% 14.9% -54.45% -53.51% 102.78% 0.59% 46.95% 16.9% 253.94% 12.61%
% of Gross Profit 149.3% 193.91% 38.21% 683.87%
Depreciation & Amortization $1.006M $944.0K $257.0K $273.0K $304.0K $324.0K $336.0K $175.0K $84.00K $75.00K $68.00K $60.00K
YoY Change 6.57% 267.32% -5.86% -10.2% -6.17% -3.57% 92.0% 108.33% 12.0% 10.29% 13.33%
% of Gross Profit 3.77% 9.33% 0.97% 10.71%
Operating Expenses $76.27M $19.61M $10.16M $8.843M $19.42M $55.90M $33.37M $37.48M $22.81M $16.44M $4.718M $5.340M
YoY Change 288.83% 93.03% 14.9% -54.45% -65.27% 67.54% -10.98% 64.29% 38.75% 248.52% -11.65%
Operating Profit -$49.60M -$42.51M $7.729M -$5.609M -$20.34M -$55.90M -$33.37M -$37.48M -$22.81M -$16.44M -$4.718M
YoY Change 16.7% -649.94% -237.8% -72.42% -63.62% 67.54% -10.98% 64.29% 38.75% 248.52%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Interest Expense $3.555M $335.0K $226.0K $4.785M $4.858M $5.469M $5.776M $5.511M $2.671M $1.605M $157.0K $160.0K
YoY Change 961.19% 48.23% -95.28% -1.5% -11.17% -5.32% 4.81% 106.33% 66.42% 922.29% -1.88%
% of Operating Profit 2.92%
Other Income/Expense, Net $3.555M $176.0K -$16.25M -$7.185M -$4.207M -$689.0K -$10.06M $20.95M -$31.82M -$8.034M -$528.0K
YoY Change 1919.89% -101.08% 126.17% 70.79% 510.6% -93.15% -148.03% -165.83% 296.12% 1421.59%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Pretax Income -$46.05M -$42.30M -$8.500M -$12.80M -$24.54M -$56.59M -$43.43M -$16.53M -$54.64M -$24.48M -$5.246M -$110.0K
YoY Change 8.86% 397.65% -33.59% -47.85% -56.63% 30.31% 162.71% -69.74% 123.22% 366.58% 4669.09%
Income Tax $0.00 -$786.0K $34.00K -$34.00K -$22.00K -$126.0K -$43.00K -$15.00K $26.00K -$22.00K -$20.00K -$40.00K
% Of Pretax Income
Net Earnings -$46.05M -$41.54M -$8.555M -$12.76M -$24.52M -$56.47M -$43.39M -$16.52M -$54.66M -$24.46M -$5.226M -$70.00K
YoY Change 10.85% 385.6% -32.95% -47.97% -56.57% 30.15% 162.69% -69.79% 123.53% 367.95% 7365.71%
Net Earnings / Revenue -167.69% -397.24% -29.86% -96.03% -191.0%
Basic Earnings Per Share -$1.30 -$1.20 -$2.11 -$3.21
Diluted Earnings Per Share -$1.30 -$1.20 -$2.11 -$3.21 -$13.25M -$50.42M -$47.16M -$18.15M -$118.8M -$163.0M -$34.87M -$466.7K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Cash & Short-Term Investments $67.74M $82.80M $112.3M $4.210M $3.220M $21.67M $42.23M $67.77M $51.32M $10.26M $1.970M $2.540M
YoY Change -18.19% -26.3% 2568.55% 30.75% -85.14% -48.69% -37.69% 32.05% 400.19% 420.81% -22.44%
Cash & Equivalents $43.05M $65.50M $112.3M $4.210M $3.220M $18.41M $10.87M $16.76M $32.32M $10.26M $1.970M $2.540M
Short-Term Investments $24.69M $17.40M $0.00 $3.260M $31.36M $51.00M $19.00M
Other Short-Term Assets $1.824M $1.900M $1.182M $1.590M $1.560M $1.910M $2.760M $1.530M $2.760M $0.00 $50.00K $40.00K
YoY Change -4.0% 60.74% -25.66% 1.92% -18.32% -30.8% 80.39% -44.57% -100.0% 25.0%
Inventory
Prepaid Expenses
Receivables $16.12M $7.200M $1.421M $2.440M $1.870M $0.00 $2.010M $5.000M
Other Receivables $1.258M $1.100M $107.0K $140.0K $0.00 $140.0K $0.00 $60.00K
Total Short-Term Assets $86.94M $93.00M $115.1M $8.380M $6.630M $23.72M $47.00M $74.36M $54.08M $10.28M $2.040M $2.610M
YoY Change -6.52% -19.17% 1272.98% 26.4% -72.05% -49.53% -36.79% 37.5% 426.07% 403.92% -21.84%
Property, Plant & Equipment $1.526M $1.800M $2.025M $2.390M $3.010M $1.750M $2.000M $1.970M $400.0K $350.0K $380.0K $320.0K
YoY Change -15.22% -11.11% -15.27% -20.6% 72.0% -12.5% 1.52% 392.5% 14.29% -7.89% 18.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $20.00M $15.42M $0.00 $3.250M $8.200M
YoY Change -100.0% 29.68% -100.0% -60.37%
Other Assets $9.935M $700.0K $438.0K $440.0K $870.0K $1.270M $210.0K $360.0K $110.0K $3.080M $10.00K $0.00
YoY Change 1319.29% 59.82% -0.45% -49.43% -31.5% 504.76% -41.67% 227.27% -96.43% 30700.0%
Total Long-Term Assets $85.39M $22.50M $17.89M $2.830M $3.880M $3.030M $5.460M $10.53M $510.0K $3.430M $390.0K $320.0K
YoY Change 279.51% 25.8% 531.98% -27.06% 28.05% -44.51% -48.15% 1964.71% -85.13% 779.49% 21.88%
Total Assets $172.3M $115.5M $132.9M $11.21M $10.51M $26.75M $52.46M $84.89M $54.59M $13.71M $2.430M $2.930M
YoY Change
Accounts Payable $13.99M $3.600M $516.0K $1.170M $4.910M $3.720M $7.880M $470.0K $4.910M $1.670M $390.0K $300.0K
YoY Change 288.53% 597.67% -55.9% -76.17% 31.99% -52.79% 1576.6% -90.43% 194.01% 328.21% 30.0%
Accrued Expenses $14.96M $3.000M $2.878M $5.800M $280.0K $4.630M $5.980M $2.230M $980.0K $780.0K
YoY Change 398.63% 4.24% -50.38% 1971.43% -93.95% 127.55% 25.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $42.25M $4.700M $15.00K $560.0K $240.0K $3.550M $3.520M $160.0K $3.440M $30.00K $3.880M $50.00K
YoY Change 798.94% 31233.33% -97.32% 133.33% -93.24% 0.85% 2100.0% -95.35% 11366.67% -99.23% 7660.0%
Total Short-Term Liabilities $73.72M $11.70M $4.230M $7.540M $5.430M $12.00M $11.51M $6.640M $8.340M $3.930M $5.240M $1.130M
YoY Change 530.09% 176.6% -43.9% 38.86% -54.75% 4.26% 73.34% -20.38% 112.21% -25.0% 363.72%
Long-Term Debt $0.00 $12.80M $6.000K $68.07M $77.51M $78.50M $89.96M $91.17M $18.53M $18.12M $90.00K $40.00K
YoY Change -100.0% 213233.33% -99.99% -12.18% -1.26% -12.74% -1.33% 392.01% 2.26% 20033.33% 125.0%
Other Long-Term Liabilities $36.74M $5.200M $1.587M $2.010M $2.020M $2.810M $8.500M $5.770M $37.84M $15.97M $2.810M $2.390M
YoY Change 606.6% 227.66% -21.04% -0.5% -28.11% -66.94% 47.31% -84.75% 136.94% 468.33% 17.57%
Total Long-Term Liabilities $36.74M $18.00M $1.593M $70.08M $79.53M $81.31M $98.46M $96.94M $56.37M $34.09M $2.900M $2.430M
YoY Change 104.13% 1029.94% -97.73% -11.88% -2.19% -17.42% 1.57% 71.97% 65.36% 1075.52% 19.34%
Total Liabilities $110.5M $29.70M $5.823M $77.62M $84.96M $93.31M $110.0M $103.6M $64.71M $38.02M $8.150M $3.560M
YoY Change 271.93% 410.05% -92.5% -8.64% -8.95% -15.15% 6.17% 60.07% 70.2% 366.5% 128.93%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Basic Shares Outstanding 35.45M 34.49M 29.77M 3.981M
Diluted Shares Outstanding 29.77M 3.981M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $489.99 Million

About ZEVRA THERAPEUTICS, INC.

Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 65 full-time employees. The company went IPO on 2015-04-16. The firm has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.

Industry: Pharmaceutical Preparations Peers: Bright Green Corp HARROW, INC. Citius Pharmaceuticals, Inc. JOHNSON & JOHNSON OMEROS CORP Rain Oncology Inc. ProPhase Labs, Inc. Satsuma Pharmaceuticals, Inc. Terns Pharmaceuticals, Inc. Xeris Biopharma Holdings, Inc.